Elanco Animal Health Inc

Elanco Animal Health Inc(ELAN)股票分析

$23.550

+0.009 (+0.04%)收盤時

Loading chart…
最高
24.110
開盤
23.870
成交量加權均價
23.69
成交量
5.17M
市值
7.05B
最低
23.410
成交金額
122.39M
企業價值/稅息折舊攤銷前利潤(TTM)
13.07

Elanco Animal Health Incorporated is an animal health company. The Company is engaged in delivering products and services to prevent and treat disease in farm animals and pets. It serves animals across species, including dogs, cats, cattle, poultry, swine and sheep. Its pet health products help pets live longer, healthier and more active lives. Its pet health portfolio is focused on parasiticides, dermatology, vaccines and pain/other therapeutics. It includes parasiticide portfolios in the pet health market based on indications, species and formulations, with products that protect pets from fleas, ticks and internal parasites. It offers Advantage, K-9 Advantix, Advocate, and AdTab, which are over-the-counter treatments for the prevention and elimination of fleas and ticks. Its farm animal products help producers improve animal health and wellbeing. It offers a farm animal portfolio of products for cattle including beef and dairy, poultry, swine and sheep.

AI 分析 of Elanco Animal Health Inc (ELAN)

買進

Elanco Animal Health Inc is a good buy right now due to its current price of $23.55, which is significantly lower than the median analyst price target of $32, indicating a potential upside of 31.3%. Additionally, the company's gross margin has improved to 48.17% in Q2 2026, reflecting strong operational efficiency. However, a risk to consider is the negative net income reported in Q4 2025 of -276 million USD, which highlights ongoing profitability challenges.

分析師評級(11)

上檔空間 +8.28%
持有
5 買進
6 持有
0 賣出
目前: 23.55
最低
22.00
平均
25.50
最高
30.00

KeyBanc

2026-08-06

目標價

$30

增持

Citi

2026-08-06

目標價

$34

買進

Morgan Stanley

2026-07-22

目標價

$26

Equal Weight

TD Cowen

2026-06-18

目標價

$32

買進

Morgan Stanley

2026-05-15

目標價

$23

Equal Weight

估值指標

Elanco Animal Health Inc(ELAN)目前預期本益比為 17.36,5 年平均預期本益比為 17.71。

預期本益比

合理
5 年均值 P/E
17.71
目前P/E
17.36
高估
22.06
低估
13.37

預期 EV/EBITDA

合理
5 年均值 EV/EBITDA
13.64
目前EV/EBITDA
13.07
高估
16.49
低估
10.80

預期股價營收比

合理
5 年均值 P/S
1.80
目前P/S
2.18
高估
2.36
低估
1.24

Alphio AI 對 ELAN 的價格情境

情境價格取自當年最後一個月度預測區間。機率為固定的模型權重(25 / 50 / 25),不構成保證。

樂

樂觀

樂觀 · 25%ELAN

$13.97

情境價格

基

基準

基準 · 50%ELAN

$13.55

情境價格

悲

悲觀

悲觀 · 25%ELAN

$10.58

情境價格

持有 ELAN 的大戶

B

Blackhill Capital, Inc

+ 持有ELAN

+10.72%

3個月報酬率

H

Hardman Johnston Global Advisors LLC

+ 持有ELAN

-1.71%

3個月報酬率

B

Black Creek Investment Management Inc.

+ 持有ELAN

-2.89%

3個月報酬率

事件時間軸

2026-08-26 (ET)

09:00:00

Elanco Animal Health Completes 25,000-SF Manufacturing Expansion

2026-08-07 (ET)

15:00:00

Elanco Receives FDA Emergency Authorization for CLiK Extra to Prevent New World Screwworm Infestations

2026-08-05 (ET)

07:00:00

Elanco Reports Q2 Revenue of $1.37B, Beating Consensus

07:00:00

Elanco Animal Health Raises FY26 Revenue Outlook to $5.09B-$5.14B

2026-06-18 (ET)

07:30:00

Elanco Animal Health Establishes Elanco Ventures Investment Platform with $25M Commitment

資訊

ELAN 常見問題 —— 由 Alphio AI 解答

Elanco Animal Health Incorporated is an animal health company. The Company is engaged in delivering products and services to prevent and treat disease in farm animals and pets. It serves animals across species, including dogs, cats, cattle, poultry, swine and sheep. Its pet health products help pets live longer, healthier and more active lives. Its pet health portfolio is focused on parasiticides, dermatology, vaccines and pain/other therapeutics. It includes parasiticide portfolios in the pet health market based on indications, species and formulations, with products that protect pets from fleas, ticks and internal parasites. It offers Advantage, K-9 Advantix, Advocate, and AdTab, which are over-the-counter treatments for the prevention and elimination of fleas and ticks. Its farm animal products help producers improve animal health and wellbeing. It offers a farm animal portfolio of products for cattle including beef and dairy, poultry, swine and sheep. It operates in the Healthcare sector (PHARMACEUTICAL PREPARATIONS industry).

Elanco Animal Health Inc is a good buy right now due to its current price of $23.55, which is significantly lower than the median analyst price target of $32, indicating a potential upside of 31.3%. Additionally, the company's gross margin has improved to 48.17% in Q2 2026, reflecting strong operational efficiency. However, a risk to consider is the negative net income reported in Q4 2025 of -276 million USD, which highlights ongoing profitability challenges.

11 analysts cover ELAN: 5 rate it Buy, 6 Hold and 0 Sell. The average price target is 25.50.

暫無貼文

註冊或登入後參與討論

本頁僅供研究參考,不構成投資建議。模型可能出錯。過往表現不代表未來結果。

開始交易